• On 27 June 2026, EyePoint, Inc. (NasdaqGM:EYPT) was added to multiple Russell growth and small‑cap benchmarks, including the Russell 3000E Growth, 3000 Growth, 2500 Growth, 2000 Growth, Microcap Growth, and Small Cap Comp Growth indices.
• This broad index inclusion widens EyePoint’s exposure to index‑tracking and quantitative investors, potentially reshaping its shareholder base and liquidity profile.
• We’ll now examine how EyePoint’s addition to several Russell growth and small‑cap indices may influence its DURAVYU‑focused investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

EyePoint Investment Narrative Recap

To own EyePoint today, you need to believe DURAVYU can successfully transition the company from minimal current revenue to a sustainable retinal franchise, despite ongoing losses and heavy dependence on a single asset. The Russell index additions broaden visibility and may support liquidity, but they do not change the central near term catalyst of Phase 3 DURAVYU readouts or the key risk of any delay or setback extending EyePoint’s period of very limited revenue and high cash burn.

The most relevant recent update alongside the index news is the May 14 confirmation that the independent DSMC recommended EyePoint’s pivotal DURAVYU Phase 3 wet AMD trials (LUGANO and LUCIA) continue without changes, with topline data expected to begin emerging in mid 2026. This keeps the DURAVYU timeline intact at a time when EyePoint’s Q1 2026 results showed net revenue of under US$1 million and a net loss of about US$84.8 million, underscoring how critical those data remain.

Yet beneath the broader index inclusion, investors should be aware that EyePoint still faces concentrated late stage risk around DURAVYU and the company’s limited cash runway into 2027...

EyePoint's narrative projects $354.2 million revenue and $69.9 million earnings by 2029.

Uncover how EyePoint's forecasts yield a $40.54 fair value, a 173% upside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts focus on whether EyePoint’s cash plus US$172 million of financing can truly support the business into Q4 2027, especially when they were only forecasting revenue to reach about US$53.2 million and earnings of roughly US$11.1 million by 2029, which shows how differently you might view today’s index news depending on how you weigh that refinancing risk.

Explore 3 other fair value estimates on EyePoint - why the stock might be worth just $40.54!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.